Interleukin-34 inhibits hepatitis B virus replication in vitro and in vivo.
The hepatitis B virus (HBV) infection could activate the immune system and induce extensive inflammatory response. As the most important inflammatory factor, interleukins are critical for anti-viral immunity. Here we investigated whether interleukin-34 (IL-34) play a role in HBV infection.In this st...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5470710?pdf=render |
id |
doaj-358d70787562430ab66402177186b5e5 |
---|---|
record_format |
Article |
spelling |
doaj-358d70787562430ab66402177186b5e52020-11-25T01:01:39ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01126e017960510.1371/journal.pone.0179605Interleukin-34 inhibits hepatitis B virus replication in vitro and in vivo.Sheng-Tao ChengHua TangJi-Hua RenXiang ChenAi-Long HuangJuan ChenThe hepatitis B virus (HBV) infection could activate the immune system and induce extensive inflammatory response. As the most important inflammatory factor, interleukins are critical for anti-viral immunity. Here we investigated whether interleukin-34 (IL-34) play a role in HBV infection.In this study, we first found that both serum IL-34 and IL-34 mRNA in PBMCs in chronic HBV patients was significantly decreased compared to the healthy controls. Furthermore, both IL-34 protein and mRNA levels were declined hepatoma cells expressing HBV. In addition, the clinical parameters analysis found that serum IL-34 was significantly associated with HBV DNA (P = 0.0066), ALT (P = 0.0327), AST (P = 0.0435), TB (P = 0.0406), DB (P = 0.0368) and AFP (P = 0.0225). Correlation analysis also found that serum IL-34 negatively correlated with HBV DNA copies, ALT and AST. In vitro studies found that IL-34 treatment in HepAD38 and HepG2.2.15 cells markedly inhibited HBV DNA, total RNA, 3.5kb mRNA and HBc protein. In vivo studies further demonstrated IL-34 treatment in HBV transgenic mice exhibited greater inhibition on HBV DNA, total RNA, 3.5kb mRNA and HBc protein, suggesting the effect to IL-34 on HBV is likely due to host innate or adaptive immune response.Our study identified a novel interleukin, IL-34, which has anti-viral activity in HBV replication in hepatocytes in vitro and in vivo. These data suggest a rationale for the use of IL-34 in the HBV treatment.http://europepmc.org/articles/PMC5470710?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sheng-Tao Cheng Hua Tang Ji-Hua Ren Xiang Chen Ai-Long Huang Juan Chen |
spellingShingle |
Sheng-Tao Cheng Hua Tang Ji-Hua Ren Xiang Chen Ai-Long Huang Juan Chen Interleukin-34 inhibits hepatitis B virus replication in vitro and in vivo. PLoS ONE |
author_facet |
Sheng-Tao Cheng Hua Tang Ji-Hua Ren Xiang Chen Ai-Long Huang Juan Chen |
author_sort |
Sheng-Tao Cheng |
title |
Interleukin-34 inhibits hepatitis B virus replication in vitro and in vivo. |
title_short |
Interleukin-34 inhibits hepatitis B virus replication in vitro and in vivo. |
title_full |
Interleukin-34 inhibits hepatitis B virus replication in vitro and in vivo. |
title_fullStr |
Interleukin-34 inhibits hepatitis B virus replication in vitro and in vivo. |
title_full_unstemmed |
Interleukin-34 inhibits hepatitis B virus replication in vitro and in vivo. |
title_sort |
interleukin-34 inhibits hepatitis b virus replication in vitro and in vivo. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2017-01-01 |
description |
The hepatitis B virus (HBV) infection could activate the immune system and induce extensive inflammatory response. As the most important inflammatory factor, interleukins are critical for anti-viral immunity. Here we investigated whether interleukin-34 (IL-34) play a role in HBV infection.In this study, we first found that both serum IL-34 and IL-34 mRNA in PBMCs in chronic HBV patients was significantly decreased compared to the healthy controls. Furthermore, both IL-34 protein and mRNA levels were declined hepatoma cells expressing HBV. In addition, the clinical parameters analysis found that serum IL-34 was significantly associated with HBV DNA (P = 0.0066), ALT (P = 0.0327), AST (P = 0.0435), TB (P = 0.0406), DB (P = 0.0368) and AFP (P = 0.0225). Correlation analysis also found that serum IL-34 negatively correlated with HBV DNA copies, ALT and AST. In vitro studies found that IL-34 treatment in HepAD38 and HepG2.2.15 cells markedly inhibited HBV DNA, total RNA, 3.5kb mRNA and HBc protein. In vivo studies further demonstrated IL-34 treatment in HBV transgenic mice exhibited greater inhibition on HBV DNA, total RNA, 3.5kb mRNA and HBc protein, suggesting the effect to IL-34 on HBV is likely due to host innate or adaptive immune response.Our study identified a novel interleukin, IL-34, which has anti-viral activity in HBV replication in hepatocytes in vitro and in vivo. These data suggest a rationale for the use of IL-34 in the HBV treatment. |
url |
http://europepmc.org/articles/PMC5470710?pdf=render |
work_keys_str_mv |
AT shengtaocheng interleukin34inhibitshepatitisbvirusreplicationinvitroandinvivo AT huatang interleukin34inhibitshepatitisbvirusreplicationinvitroandinvivo AT jihuaren interleukin34inhibitshepatitisbvirusreplicationinvitroandinvivo AT xiangchen interleukin34inhibitshepatitisbvirusreplicationinvitroandinvivo AT ailonghuang interleukin34inhibitshepatitisbvirusreplicationinvitroandinvivo AT juanchen interleukin34inhibitshepatitisbvirusreplicationinvitroandinvivo |
_version_ |
1725208128924942336 |